PLOS ONE Publishes Data On Allarity Therapeutics' DRP Companion Diagnostic For Dovitinib
Portfolio Pulse from Happy Mohamed
Allarity Therapeutics (NASDAQ:ALLR) announced the publication of its clinical validation of a novel drug-specific DRP®-companion diagnostic (CDx) for dovitinib in the peer-reviewed journal PLOS ONE. The DRP®-Dovitinib CDx was able to identify a subgroup of advanced renal cell carcinoma (RCC) patients that have improved clinical benefit from treatment with dovitinib. The DRP®-Dovitinib CDx is a complex transcriptomic signature comprising 58 mRNA biomarkers that are collectively predictive of tumor response to the drug. Dovitinib is currently being advanced by Allarity in an ongoing Phase 1b clinical study exploring the potential synergy of dovitinib and stenoparib for the treatment of advanced solid tumors, including ovarian cancer.
August 30, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allarity Therapeutics' DRP®-Dovitinib CDx has shown promise in identifying patients who could benefit from dovitinib treatment. This could potentially lead to increased demand for the company's products and services.
The publication of the clinical validation of Allarity Therapeutics' DRP®-Dovitinib CDx in a peer-reviewed journal adds credibility to the company's product. This could potentially lead to increased demand for the company's products and services, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100